CATEGORY: WOMEN’S HEALTH
Gepotidacin, a first-in-class oral antibiotic that attacks bacteria in a way no existing drug does, cured uncomplicated urinary tract infections at least as reliably as the standard antibiotic nitrofurantoin in two randomized trials enrolling more than 3,000 women and adolescent girls—and in one of the two trials it did significantly better, with 58.5% cured versus 43.6%.1
A Common Infection and a Thinning Toolkit
Urinary tract infections are among the most common bacterial infections women get, and the short list of reliable oral treatments has been shrinking as resistance spreads—the study authors note that gepotidacin remains active against bacteria that have developed resistance to existing drugs. The drug works by jamming two of the enzymes bacteria use to copy their own DNA, gripping them at a binding site no current antibiotic uses. Because it leans on both enzymes in a balanced way, a single mutation is unlikely to defeat it—like changing the locks on two doors at once, so that one copied key no longer gets a burglar in.
Two Twin Trials and a Strict Definition of Cured
The EAGLE-2 and EAGLE-3 trials, run at 219 centers worldwide, randomly assigned non-pregnant women and girls aged 12 and older with symptoms and urine evidence of infection to a five-day course of either gepotidacin or nitrofurantoin, a long-standing first-choice UTI antibiotic. Neither patients nor doctors knew who received which. About ten days after starting treatment, each participant was scored against an unusually strict double bar: success meant symptoms completely resolved and laboratory tests confirming the bacteria were cleared, with no other antibiotics needed. That strictness explains why the cure numbers look lower than everyday experience suggests—partial improvement counted as failure. Both trials were stopped early for efficacy at a planned interim checkpoint, so the primary results come from the roughly 600 patients per trial evaluable at that point.
Matched in One Trial, Ahead in the Other
The trials were designed to ask a modest question—is the new drug at least no worse?—and one of them returned a stronger answer. In EAGLE-2, 162 of 320 women on gepotidacin (50.6%) met the strict cure standard versus 135 of 287 (47.0%) on nitrofurantoin: statistically no worse. In EAGLE-3, gepotidacin was superior: 162 of 277 cured (58.5%) versus 115 of 264 (43.6%), an adjusted difference of 14.6 percentage points (95% confidence interval, 6.4 to 22.8). For a field that has not seen a genuinely new type of oral UTI antibiotic reach late-stage trials in a generation, matching the standard was the goal and beating it was the surprise the design allowed for.
Loose Stools, Not Serious Harms
The tradeoff showed up in the gut: diarrhea was the most common side effect of gepotidacin, affecting 14% of patients in one trial and 18% in the other, versus nausea in about 4% on nitrofurantoin. Cases were mostly mild or moderate, and no life-threatening or fatal events occurred in either trial. The research was funded by GSK, gepotidacin’s maker, together with BARDA, the U.S. biomedical preparedness agency that co-funds antibiotic development precisely because resistant infections are a public health threat.
Key Takeaways
- Gepotidacin, the first genuinely new type of oral UTI antibiotic in a generation, matched nitrofurantoin in both trials and outperformed it in one, curing 58.5% versus 43.6%.
- “Cured” required both complete symptom resolution and lab-confirmed clearance of the bacteria—a stricter bar than how the word is used day to day.
- The most common side effect was diarrhea, mostly mild to moderate; no serious drug-related harms occurred.
- A new antibiotic class matters beyond any single prescription: it stays active against bacteria already resistant to current UTI drugs.
References
- Wagenlehner F, Perry CR, Hooton TM, et al. Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials. Lancet. 2024;403(10428):741–755. link